- Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
-
Kim KI
- KMID: 2414912
- Korean Circ J.
- 2018 May;48(5):430-432.
- doi: 10.4070/kcj.2018.0085
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice
-
Kim NH, Kim SG
- KMID: 2390865
- J Korean Diabetes.
- 2017 Sep;18(3):135-140.
- doi: 10.4093/jkd.2017.18.3.135
Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are newer classes of glucose-lowering agents that are currently widely used in clinical practice. Their glycemic efficacy and cardiovascular... -
- CITED
-
- Close
- SHARE
-
- Close
- Novel Therapies for Type 2 Diabetes Mellitus
-
Ko JM
- KMID: 1819674
- J Korean Soc Pediatr Endocrinol.
- 2009 Jun;14(1):11-18.
Type 2 diabetes mellitus (T2DM) is a progressive disorder caused by a combination of insulin resistance and betacell dysfunction. The role of new hormones and systems in maintaining blood glucose... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of DPP-4 Inhibitors
-
Kim NH, Kim SG
- KMID: 2173918
- J Korean Diabetes.
- 2013 Sep;14(3):111-119.
- doi: 10.4093/jkd.2013.14.3.111
During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis
-
Cho EH
- KMID: 2173923
- J Korean Diabetes.
- 2013 Sep;14(3):138-142.
- doi: 10.4093/jkd.2013.14.3.138
Recently, dipeptidylpeptidase-4 (DPP-4) inhibitors have been widely used as a second-line therapy for type 2 diabetes because of their glucose-lowering efficacy, weight neutral effects and minimal hypoglycemia. However, there have... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
-
Jeong IK
- KMID: 2416256
- J Lipid Atheroscler.
- 2018 Jun;7(1):32-41.
- doi: 10.12997/jla.2018.7.1.32
In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes.... -
- CITED
-
- Close
- SHARE
-
- Close
- Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
-
Lim SW, Jin JZ, Jin L, Jin J, Li C
- KMID: 2381580
- Korean J Intern Med.
- 2015 Nov;30(6):759-770.
- doi: 10.3904/kjim.2015.30.6.759
Despite strict pre- and post-transplantation screening, the incidence of new-onset diabetes after transplantation (NODAT) remains as high as 60%. This complication affects the risk of cardiovascular events and patient and... -
- CITED
-
- Close
- SHARE
-
- Close
- New and emerging drugs in type 2 diabetes
-
Park IB
- KMID: 2256406
- Korean J Med.
- 2007 May;72(5):446-450.
Recent advances in understanding insulin secretion, action and signaling have led to the development of new pharmacological agents. Several new emerging drugs and drug classes for the management of diabetes... -
- CITED
-
- Close
- SHARE
-
- Close
- New Therapeutics for Diabetes Using Incretin Hormone
-
Oh S
- KMID: 2259281
- Korean J Med.
- 2011 Jun;80(6):625-634.
New therapeutics for type 2 diabetes using incretin hormone were introduced recently. Incretin-based therapies consist of two types: GLP-1 agonists mainly acting on the GLP-1 receptor and dipeptidyl peptidase 4... -
- CITED
-
- Close
- SHARE
-
- Close
- Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
-
Kim SH, Yoo JH, Lee WJ, Park CY
- KMID: 2354607
- Diabetes Metab J.
- 2016 Oct;40(5):339-353.
- doi: 10.4093/dmj.2016.40.5.339
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
-
Lee SJ, Lee KH, Oh HG, Seo HJ, Jeong SJ, Kim CH
- KMID: 2470293
- J Obes Metab Syndr.
- 2019 Dec;28(4):254-261.
- doi: 10.7570/jomes.2019.28.4.254
BACKGROUND: Randomized controlled trials demonstrated lowering risks of cardiovascular events with sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk. We analyzed the... -
- CITED
-
- Close
- SHARE
-
- Close
- Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation
-
Broxmeyer
- KMID: 1780121
- Korean J Intern Med.
- 2013 Nov;28(6):639-645.
- doi: 10.3904/kjim.2013.28.6.639
Dipeptidylpeptidase (DPP) 4, also known as CD26, is an enzyme present on the surface of a number of different cell types. It is also found within cells and as a... -
- CITED
-
- Close
- SHARE
-
- Close
- Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
-
Sicras-Mainar A, Navarro-Artieda R
- KMID: 2280660
- Diabetes Metab J.
- 2015 Feb;39(1):74-81.
- doi: 10.4093/dmj.2015.39.1.74
BACKGROUND: To evaluate resource use and health costs due to the combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal impairment in routine clinical practice. METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer
-
Amin S, Boffetta P, Lucas AL
- KMID: 2412062
- Gut Liver.
- 2016 Sep;10(5):665-671.
- doi: 10.5009/gnl15451
Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Incretin-Based Therapies on Diabetic Microvascular Complications
-
Kang YM, Jung CH
- KMID: 2389811
- Endocrinol Metab.
- 2017 Sep;32(3):316-325.
- doi: 10.3803/EnM.2017.32.3.316
The morbidity and mortality associated with diabetic complications impose a huge socioeconomic burden worldwide. Therefore, the ultimate goal of managing diabetes mellitus (DM) is to lower the risk of macrovascular... -
- CITED
-
- Close
- SHARE
-
- Close
- Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
-
Son JW, Kim S
- KMID: 2174010
- Diabetes Metab J.
- 2015 Oct;39(5):373-383.
- doi: 10.4093/dmj.2015.39.5.373
Dipeptidyl peptidase 4 (DPP4) inhibitors have been touted as promising antihyperglycemic agents due to their beneficial effects on glycemia without inducing hypoglycemia or body weight gain and their good tolerability.... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors Influencing Glycemic Control Response of Sitagliptin
-
Kim GW, Kim JH, Lee MY, Shin JY, Shin YG, Ha EH, Chung CH
- KMID: 2173938
- J Korean Diabetes.
- 2013 Dec;14(4):206-211.
- doi: 10.4093/jkd.2013.14.4.206
BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to reduce blood glucose in type 2 diabetes by prolonging the activity of circulating incretins. However, the factors that affect the efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
-
Ahn CH, Lim S
- KMID: 2449891
- J Stroke.
- 2019 May;21(2):139-150.
- doi: 10.5853/jos.2019.00038
Patients with hyperglycemia are at a high risk of cardio- and cerebrovascular diseases. Diabetes patients also have poor outcomes after cerebrovascular disease development. Several classes of drugs are used for... -
- CITED
-
- Close
- SHARE
-
- Close
- The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial and Its Clinical Impact on Patterns of Prescription for Anti-Diabetes Medication
-
Kwon HS
- KMID: 2362978
- J Korean Diabetes.
- 2016 Dec;17(4):225-232.
- doi: 10.4093/jkd.2016.17.4.225
Since 2008, the Food and Drug Administration has required cardiovascular (CV) safety trials for all anti-diabetic medications available in the USA. Thus, new agents like dipeptidyl peptidase 4 inhibitors and... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
-
Oh TJ, Jung HS, Bae JH, Kim YG, Park KS, Cho YM, Park KS, Kim SY
- KMID: 2158036
- J Korean Med Sci.
- 2013 Jun;28(6):881-887.
- doi: 10.3346/jkms.2013.28.6.881
We investigated characteristics associated with the efficacy of dipeptidyl peptidase-4 inhibitors (DPP4i) in Korean patients with type 2 diabetes. We reviewed medical records of 477 patients who had taken sitagliptin... -
- CITED
-
- Close
- SHARE
-
- Close
